A+KIDS, a web-based antipsychotic registry for North Carolina youths: an alternative to prior authorization

Autor: Trista Pfeiffenberger, Larry Jarrett Barnhill, Guy Palmes, Lynn M. Wegner, Joel F. Farley, Steven E. Wegner, Linmarie Sikich, David Wei, Troy Trygstad, Randell Best, John Diamond, Brian Sheitman, Robert Christian, Jerry McKee, Alan Chrisman
Rok vydání: 2013
Předmět:
Zdroj: Psychiatric services (Washington, D.C.). 64(9)
ISSN: 1557-9700
Popis: The rise in use of antipsychotics among U.S. children is well documented. Compliance rates with current safety-monitoring guidelines are low. In response, the North Carolina Division of Medical Assistance established the Antipsychotics-Keeping It Documented for Safety (A+KIDS) registry. The initial objectives of the project were to successfully establish a Web-based safety registry and to obtain and evaluate clinical information derived from the registry.In April 2011, A+KIDS began asking prescribers of antipsychotics for children age 12 and under to respond to a set of questions regarding dose, indication, and usage history. Antipsychotic registrations were examined by linking North Carolina Medicaid prescription claims to registry entries. Prescribers were classified into different types, and the number of patients and registrations per prescriber were examined.In the initial six months, 730 prescribers registered 5,532 patients, 19% below age seven. By month 6 of the registry, 72% of all fills were registered with the program. Top diagnosis groups for registry patients were unspecified mood disorders, autism spectrum disorders, and disruptive behavior disorders. Top target symptoms were aggression (48%), irritability (19%), and impulsivity (11%). Psychosis accounted for 5% of the target symptoms. Twenty-eight percent of children were receiving no form of psychotherapy. Twenty-five percent of all A+KIDS prescribers were responsible for 81% of the registrations.The A+KIDS registry initiative has been successful, as measured by rapid uptake, and is providing clinical information not available from claims data alone. Future efforts will allow for detailed examinations of antipsychotic utilization and further safety improvement.
Databáze: OpenAIRE